1986
 
 - The company was incorporated on 26th December as a Private Limited
 company and was converted into a Public Limited company with effect
 from 30-4-1992.  The company is registered with the Registrar of
 Companies, Andhra Pradesh at Hyderabad.  The chief promoters of the
 Company are Shri P.V. Ramaprasad Reddy and Shri K. Nityananda Reddy.
 
 - Aurobindo Pharma Limited is one of the leading manufacturers of
 life
 saving anti-biotic bulk drugs in India with excellent track record
 of
 profitability and growth.
 
 - The Company has developed inhouse technology for manufacture of
 the
 bulk drugs as well as formulations.
 
 - The Company is one of the largest manufacturers of Ampicillin and
 Cloxacillin in India.
 
 1992
 
 - Another unit was also set up for the manufacture of CMIC Chloride,
 a
 bulk drug intermediate at Pashamylaram, near Hyderabad.  Through
 another Company namely, Chaitanya Organics Pvt. Ltd., which is now
 being merged with Aurobindo Pharma Limited.
 
 - The Company issued Bonus Shares in the ratio of 1:1 in May, in the
 ratio of 2:1 in June, 1993 and in the ratio of 7:20, in November
 1994.
 
 - The Company follows the Mercantile System of Accounting and
 recognises Income and Expenditure on Accrual basis.
 
 1993
 
 - The Company has set up two more units during the year, viz.,
 
 - i) Bulk drug unit at Bollaram, near Hyderabad.
 
 - ii) Formulations unit at Kukatpally, near Hyderabad.
 
 - The Company is setting up a Bulk Drug cum Formulation Plant to
 produce sterile Bulk Drugs like Ampicillin Sodium (Sterile) IP/BP,
 Cloxacillin Sodium (Sterile) IP/BP, and cephalosporins (Sterile)
 Bulk
 Drugs and Formulations in the dosage forms like sterile powder
 injectables, small volume parenterals, Capsules and Tablets.
 
 1994
 
 - The installed capacity of the Pondicherry Unit of the Company is
 increased from 204 TPA to 300 TPA during the current year
 
 - The Bollaram unit is for the manufacture of anti-biotic bulk
 drugs,
 namely Cloxacillin, and Dicloxacillin mainly for exports.
 
 - During the Year, the Company has upgraded the plant and increased
 the
 installed capacity from 78 TPA to 84 TPA.  The Company has set up a
 separate block in the same premises during the current year, 1994-95
 for manufacture of high value drugs namely Astemizole, Domeperidone,
 Famotidine and Omeprazole, with an installed capacity of 9 TPA.
 
 - The Kukatpally unit is for manufacture of pharmaceutical
 formulations
 with an installed capacity of 360 lakhs tablets and 480 lakhs
 capsules
 per annum.
 
 - During the current year the Company has increased the installed
 capacity of the merged company Chaitanya Organics Pvt. Ltd., from
 120
 TPA to 144 TPA.  Further a new bulk drug intermediate namely DCMIC
 Chloride is also manufactured in this unit from April.  The Company
 has
 also expanded the above unit by setting up a separate block for
 manufacture of Norfloxacillin and Pefloxacillin with an installed
 capacity of 60 TPA.
 
 - The Company proposed to acquire two generators of 250 KVA capacity
 each as standby arrangement.
 
 - The company has entered into domestic formulations market in 5
 States
 and plans to launch in other states shortly.
 
 - The Company has agency set-up at Srilanka, Thailand, Russia and
 Nigeria for marketing its products.  It proposes to set up its own
 marketing offices at Hongkong, Moscow and Nigeria to promote bulk
 drug
 sales.
 
 - The Company has a connected power load of 500 KVA from A.P.S.E.B. 
 In
 addition, 3 Generators of 125 KVA capacity each have been installed
 as
 a stand by arrangement.
 
 - The Company is a member of Patancheru Effluent Treatment Plant
 Limited and Jeedimetle Effluent Treatment Plant.
 
 - All the Assets and Liabilities of M/s. Chaitanya Organics Pvt. 
 Ltd.
 will be taken over by M/s. Aurobindo Pharma Ltd. with effect from
 1st
 April, on completion of amalgamation formalities.
 
 - As per the scheme of amalgamation it is proposed to issue one
 equity
 share of M/s. Aurobindo Pharma Ltd. of Rs 10/- each credited as
 fully
 paid up for every one equity share of Rs 10/- each fully paid up
 held
 in M/s. Chaitanaya Organics Pvt. Ltd. to the Shareholders of M/s.
 Chaitanya Organics Pvt. Ltd.
 
 1995
 
 - In January, Videocon International and Videocon Appliances sold a
 tranche of Aurobindo shares to the public at a premium of Rs 180.
 
 1997
 
 - Glaxo (India), the Indian subsidiary of the UK-based
 multinational,
 is understood to be negotiating with the Hyderabad-based Aurobindo
 Pharma for an alliance to meet its global bulk drug requirements.
 
 - The annual capacities now stand at 300 million of capsules and 840
 tonnes of bulk drugs.
 
 - The company proposes to manufacture fourth generation
 cephalosporins
 such as 7-ACA, cephalexin, cephatoxime and cephazolin.
 
 1998
 
 - AUROBINDO Pharma Ltd is setting up two wholly-owned subsidiaries
 in
 the US and Hong Kong to increase its presence in the international
 market.
 
 - The company is one of the largest bulk manufacturers of
 semi-synthetic penicillin (SSP) products such as ampicilin and
 Amoxycillin.  It is the world's fourth largest producer of
 ampicillins
 and fifth largest producer of amoxycillins.
 
 - The company has also launched new formulations like auronim
 Suspension in the paediatric segment.
 
 - The company has obtained the shareholders permission to invest
 ,00,000 in the share capital of Aurobindo Pharma (Miami) Inc in
 USA
 and 0,000 in the share capital of Aurobindo Pharma (Hong Kong)
 Pte
 Ltd.
 
 - The company would be launching several new formulations including
 Roxythromycin, Clarithromycin, Sporfloxocyin, besides Sephradin, a
 smei-synthetic, in the domestic market.  Among sterile products to
 be
 launched by the company are Cephazolin, Cehatoxin and Azithromycin.
 
 1999
 
 - The Hyderabad-based Aurobindo Pharma had received in-principle
 approval from the Board of Industrial and Financial Reconstruction
 (BIFR) in March to buy the plant.
 
 - APL is today the most cost-efficient producer of SSPs in India and
 a
 low cost international producer of other value added bulk drugs and
 drug intermediaries.
 
 - Aurobindo currently manufactures three types of drugs including
 cephalosporin-based formulations, drugs for gastroenterology and
 pain-related products.
 
 - The company proposes to deploy the issue proceeds to part-finance
 its
 R&D thrust and the growth of its formulations business.  APL plans
 to
 meet the further funds requirement for its capital expenditure
 programme, if any, through internal accruals.
 
 - The board of directors has allotted 5,51,000 equity shares of
 Rs.10
 each at a premium of Rs.480 per share by private placement on
 preferential basis to FIIs, FIs, MFs and bodies corporate etc.
 
 - Aurobindo Pharma Ltd, the largest domestic manufacturer of
 penicillin-based bulk antibiotics, plans to form joint ventures in
 Brazil and China by the end of financial year 1999-2000
 (April-March).
 
 2000
 
 - Aurobindo Pharma Ltd. a major producer of semi-synthetic
 penicillins
 in the country, proposes to set up two joint venture companies in
 the
 US to manufacture cephalosporins and non-cephalosporins.
 
 - Aurobindo Pharma is setting up two joint ventures for formulations
 in
 the US, with an investment of  million.
 
 - As per the scheme of Amalgamation equity shares of Aurobindo
 Pharma
 Limited will be exchanged to the shareholders of Sri Chakra Remedies
 Limited for every 100 equity shares held by them.
 
 2001
 
 - The Company has launched an exclusive anti-viral division --
 Immunus
 -- to educate and to provide preventive drug care for HIV/AIDS
 patients
 in the country.
 
 - Hyderabad based Aurobindo Pharma has restructured its management
 responsibilities in view of major growth initiatives to be taken to
 create a platform for penetrating attractive global markets. P V
 Ramaprasad Reddy, former managing director, has been appointed
 executive chairman, while K Nityananda Reddy, former joint managing
 director and co-promoter, has been appointed managing director, APL
 informed the Bombay Stock Exchange on July 4.
 
 -This new structure is expected to enable the company to concentrate
 on
 the strategies of change being pursued by it to achieve the goal of
 becoming a research and development-based international
 pharmaceutical
 company, it said, adding that the changes had received board
 approval.
 
 -Aurobindo Pharma Ltd today announced the launch two more drugs--
 Efavirenz (Viranz) and Nelfinavir (NELVEX)-- for the treatment of
 AIDS.
 
 2002
 
 -Three existing Directors, Mr Srinivas Lanka, Mr A J Kamath and Mr A
 Siva Rama Prasad have stepped down from the directorship, thus
 making
 room for appointment of independent external directors. Accordingly,
 their resignations were accepted. While Mr Srinivas Lanka will be
 considered for reappointment as non-executive independent Director,
 Mr
 A J Kamath will assume the responsibility of group financial
 advisor.
 Further, it is planned to retain the services of Mr A Siva Rama
 Prasad
 for group operations.
 
 -Aurobindo Pharma to allot further equity shares/warrants to
 promoters.
 
 -Srinivas Lanka re-inducted into the Board of Aurobindo Pharma.
 
 -Sathyamurthy appointed as Additional Director of Aurobindo Pharma.
 
 
 2003
 
 -The Board of Directors of Aurobindo Pharma Ltd has approved the
 appointment of Dr K A Balasubramanian as an additional director on
 the Board of Directors of the company. Dr Balasubramanian shall be an
 independent, non-executive director.
 
 -Aurobindo informed BSE that Citadel Aurobindo Biotech Ltd, a 50:50
 Joint venture company
 introduced Aztreonam a Monabactam Betalactam antibiotic for the first
 time in the Indian
 Pharma Market with a brand name 'TREONAM'.
 
 -Aurobindo Tongling (Datong) pharmaceuticals Ltd, China , a JV
 between APL and Shanxi Tongling Pharmaceuticals co. has set up for
 manufacture of pharmaceutical products for the local market.
 
 -With a view to manufacture Pen G, a raw material essential for the
 production of semi-synthrtic
 pencillin, Aurobindo has infused Rs 59cr in a flagship
 Aurobindo(Datong) Pharma Ltd.
 
 -Aurobindo Pharma has launched second joint venture company in US for
 the purpose
 of Research and Development.
 
 -Allots 950,000 equity shares to promoters/directors by way of
 conversion of warrants
 
 -Aurobindo Pharma has launched second joint venture company in the
 United States for the purpose of R & D in alliance with Salus
 Pharmaceuticals.
 
 
 -Aurobindo Pharma has filed around 20 patents in the areas of central
 nervous system, cardio-vascular, and anti-cholesterol segments. Out of
 this it is able to obtain 2 of them in United States of America.
 
 -UTI sold 3 pc stake from the company
 
 -Board approves the issue on a preferential basis, of an aggregate
 upto 3,100,000 equity shares of Rs.5/- each at a price of Rs.302/-
 per equity share (including a premium of Rs.297 per equity share),
 totalling up to Rs.93.62 cr
 
 -Company ropes in Merlion India Fund 1, Mauritius, for allotting 31
 lakh equity shares on a preferential basis at a price of Rs 302 per
 share, including a premium of Rs 297 per share, totalling Rs 93.62
 crore
 
 2004
 
 - Ms P. Suneela Rani, has sold 6,80,000 equity shares of Rs 5 each of
 the company, constituting 1.4 per cent of equity of its current
 paid-up equity of Rs 24.2 crore. These shares were sold in the open
 market from December 23-31 last year
 
 Aurobindo Pharma Ltdhas announced that it has received its first
 Certificate of Suitability (CoS) approval from the European
 Directorate for Quality Medicines (EDQM) for its product in the
 therapeutic segment of gastroenterology. 
 
 -Aurobindo Pharma Ltd has informed that the members at the EGM of the
 Company held on December 26, 2003 have unanimously approved the
 following special resolution : 'Issue of equity shares under
 preferential allotment guidelines of SEBI'. Further, the Company has
 also informed that delisting of securities of the company from
 Ahmedabad Stock Exchange was approved w.e.f. January 15, 2004.
 
 -Aurobindo Pharma Ltd has informed that pursuant to the application
 of the Company, its securities have been removed from the list of the
 Ahmedabad Stock Exchange (ASE) w.e.f. January 15, 2004.
 
 2005
 
 -USFDA part of Department of health and human science approves UNIT
 VIII facility as a site to manufacture APIs for the US Market.
 
 -Aurobindo AIDS drug receives US FDA clearance
 
 -Aurobindo Pharma gets EDQM approval for Flucloxacillin Sodium
 
 -Aurobindo Pharma receives approval for Sertraline Hydrochloride
 Tablets
 
 -Aurobindo Pharma receives approval for Cephalexin Capsules by US
 FDA
 
 -Aurobindo's receives final approval of Mirtazapine Orally
 Disintegrating Tablets
 
 2006
 
 -Aurobindo Pharma receives final approval of Mirtazapine ODT 45mg for
 US marketAurobindo Pharma receives final approval of Mirtazapine ODT
 45mg for US market
 
 -Aurobindo Pharma Ltd has announced that the US FDA has granted
 tentative approval for the Company's Simvastatin Tablets USP 5 mg, 10
 mg, 20 mg, 40 mg and 80 mg
 
 -Aurobindo receives US FDA approval for Didanosine (Chewable)
 Tablets
 -Aurobindo Pharma Ltd has announced that it has received the
 marketing authorization approval from Medicines Evaluation Board
 (MEB), NETHERLANDS for Mirtazapine 15, 30 and 45 mg orally
 disintegrating tablets containing the active ingredient Mirtazapine.
 
 -Aurobindo Pharma Ltd has appointed Mr. A.Mohan Rami Reddy as Company
 Secretary of the Company.
 
 -Aurobindo Pharma receives final approval for SIMVASTATIN tablets
 from USFDA.
 
 -Aurobindo arm acquires Dutch firm Pharmacin.
 
 2007
 
 - Aurobindo Pharma Ltd has received one more approval from USFDA for
 Cefadroxil capsules 500 mg.
 
 - Aurobindo Pharma Ltd has announced that on June 13, 2007 the
 Company unveiled their new Logo and Corporate Identity at a ceremony
 in Hyderabad.
 
 2008
 
 - Aurobindo Pharma Ltd has announced that the Company has received an
 approval from the US Food & Drug Administration to market its 300mg
 Cefdinir Capsules in the US market. The drug falls under the
 Anti-bacterial segment and is a generic equivalent of Abbott
 Laboratories, OMNICEF.
 
 -Aurobindo Pharma Ltd has appointed Mr. K Raghunathan as an
 Additional Director of the Company at the Board Meeting held on
 January 30, 2008.
 
 - Aurobindo Pharma Ltd has announced that the Company has been
 awarded ARV contract worth Rs 70 crores for 3 products which are WHO
 / USFDA pre-qualified by National Aids Control Organization (NACO).
 
 - Aurobindo Pharma Ltd has got final clearance from the US Food and
 Drug Administration (USFDA) to manufacture and market Didanosine
 Delayed Release capsules in 125 mg, 200 mg, 250 mg and 400 mg. The
 drug is indicated for treatment of HIV - 1 infections in adults. It
 is the generic version of Bristol Myer Squibb's Videx EC
 delayed-release capsules.
 
 2009
 
 - Aurobindo Pharma Ltd has received Swissmedic approvals for
 Amlodipine Besylate Tablets and Metformin Hydrochloride Tablets.
 
 2010
 
 - Aurobindo Pharma has received final approval from the United States
 Food and Drug Administration for its product Ceftazideme injection in
 different dosages.